Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs specializes in a wide array of BCMA recombinant antibodies, backed by extensive technical assistance to enhance experimental performance. Our experienced scientists are available around the clock to address any inquiries regarding BCMA recombinant antibodies, guaranteeing their efficacy and reliability for your research needs. Furthermore, we provide validation data and suggested protocols, empowering researchers to achieve consistent and dependable results with our antibodies.
B-cell maturation antigen (BCMA) (also named TNFRSF17) plays a crucial role in the survival and differentiation of B cells and plasma cells. Its increased expression is linked to the advancement of multiple myeloma (MM) and is indicative of a worse clinical outcome. Immunotherapies targeting BCMA have demonstrated significant efficacy and safety in MM patients who have undergone multiple lines of treatment. Therefore, the development of BCMA-specific antibodies provides a promising approach to harnessing the immune system to target and eliminate cancer cells.
BCM; B-cell maturation factor; B-cell maturation antigen; B-cell maturation protein; Tumor necrosis factor receptor superfamily member 17; TNFRSF17; CD269; TNFRSF13A.
The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13B/TALL-1/BAFF), and to lead to NF-kappaB and MAPK8/JNK activation. This receptor also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation.
Our high-quality BCMA recombinant antibodies are designed for precise targeting of the BCMA protein. Tailored through advanced engineering techniques, these antibodies exhibit enhanced efficacy and specificity, providing essential tools for researchers investigating the implications of BCMA in oncogenesis and the exploration of innovative cancer treatments. Meanwhile, we offer a diverse selection of BCMA recombinant antibodies with various formulations and conjugations, catering to a wide array of experimental requirements.
Table 1. Featured anti-BCMA recombinant antibody products at Creative Biolabs.
Cat. No. | Product Name | Target Species | Host Species | Applications |
PABL-019 | Recombinant Mouse Anti-BCMA Antibody (J22.9-xi) | Human | Mouse IgG | ELISA, FC, Neut, FuncS |
At Creative Biolabs, our BCMA recombinant antibodies are meticulously developed through a robust quality assurance framework, guaranteeing unparalleled product integrity. This comprehensive approach allows us to deliver dependable and potent BCMA recombinant antibodies tailored to meet the demands of researchers and healthcare professionals engaged in cutting-edge immunotherapy and oncology research.
Our anti-BCMA recombinant antibodies are produced using advanced biotechnological methods, which involve genetically modified cells that effectively express and secrete antibodies targeting the BCMA protein. This innovative approach ensures efficient and economical production, making our antibodies readily available for various research applications.
Featured Anti-BCMA Recombinant Antibody Production Platforms
Fig.1 Milligram-scale anti- BCMA recombinant antibody production.
Fig.2 Gram-scale anti-BCMA recombinant antibody production.
Creative Biolabs specializes in delivering innovative and high-quality anti-BCMA recombinant antibodies in various formats for research purposes.
Fig.3 Full-length anti-BCMA recombinant antibody production and modalities.
Table 2. Public drug targeting BCMA.
Highest Phase | Mechanism of Action | Product Category | Condition | Organization |
Launched - 2023 | Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 17 (TNFRSF17, BCMA, CD269)Signal Transduction Modulators | Cancer ImmunotherapyChimeric Antigen Receptor-Modified T Cells (CAR T Cells) (Second-Generation CAR) | Multiple myelomaNeuromyelitis optica | Huazhong University of Science and Tech (Originator)IASO BIOInnovent Biologics (Originator) |
Launched - 2023 | Anti-CD269 (Anti-BCMA)Anti-CD3 (T-Cell Surface Glycoprotein CD3)Signal Transduction ModulatorsT-Cell Engagers | Bispecific AntibodiesCancer ImmunotherapyHuman Monoclonal Antibodies | Multiple myeloma | Pfizer (Originator) |
Registered - 2024 | Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 17 (TNFRSF17, BCMA, CD269) | Cancer ImmunotherapyChimeric Antigen Receptor-Modified T Cells (CAR T Cells) (Second-Generation CAR) | Multiple myeloma | CARsgen Therapeutics (Originator)Hangzhou Huadong Medicine GroupShanghai Jiao Tong University (SJTU) (Originator) |
Pre-Registered | Anti-CD269 (Anti-BCMA)Anti-CD3 (T-Cell Surface Glycoprotein CD3)Signal Transduction ModulatorsT-Cell Engagers | Bispecific AntibodiesCancer Immunotherapy | Allergy, foodChronic kidney diseaseImmunoproliferative DisordersLight chain amyloidosisMultiple myelomaSmoldering myeloma | Regeneron (Originator) |
Phase III | Drugs Targeting T-Cell Surface Glycoprotein CD3Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 17 (TNFRSF17, BCMA, CD269)T-Cell Engagers | Antibody-Derived Binding ProteinsBispecific AntibodiesCancer ImmunotherapyFusion ProteinsPolypeptides, from 41 AA | Light chain amyloidosisMultiple myeloma | AbbVie (Originator)TeneoBio (Amgen) |
Phase II | Drugs Targeting G-Protein Coupled Receptor Family C Group 5 Member D (GPRC5D)Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 17 (TNFRSF17, BCMA, CD269)Signal Transduction Modulators | Cancer ImmunotherapyChimeric Antigen Receptor-Modified T Cells (CAR T Cells) | Multiple myeloma | Guangzhou Bio-gene Technology (Originator) |
Phase II | Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 17 (TNFRSF17, BCMA, CD269) | Cancer ImmunotherapyChimeric Antigen Receptor-Modified T Cells (CAR T Cells) | Autoimmune diseaseMultiple myelomaMyasthenia gravisSystemic lupus erythematosus | Cartesian Therapeutics (Originator)Dana-Farber Cancer Institute (Originator) |
Phase I/II | Anti-CD269 (Anti-BCMA)Anti-CD3 (T-Cell Surface Glycoprotein CD3)Anti-GPRC5D (G-Protein Coupled Receptor Family C Group 5 Member D)Signal Transduction ModulatorsT-Cell Engagers | Cancer ImmunotherapyFusion ProteinsPolypeptides, from 41 AATrispecific Antibodies | Multiple myeloma | Beijing Mabworks Biotech (Originator)KYinno Biotechnology (Originator) |
Phase I/II | Drugs Targeting FcgammaRIII (FCGR3; CD16)Drugs Targeting Natural Cytotoxicity Triggering Receptor 1 (NCR1; CD335; NKp46)Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 17 (TNFRSF17, BCMA, CD269)NK-Cell EngagersSignal Transduction Modulators | Cancer ImmunotherapyFusion ProteinsMultispecific AntibodiesPolypeptides, from 41 AASingle-Chain V-Domain Antibody Fragment (scFv) | CancerLight chain amyloidosisMultiple myeloma | Innate Pharma (Originator)Sanofi (Originator) |
Phase I/II | Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 17 (TNFRSF17, BCMA, CD269) | Cancer ImmunotherapyChimeric Antigen Receptor (CAR)-Modified Natural Killer (NK) Cells | Multiple myeloma | Asclepius (Suzhou) Technology (Originator)Asclepius (Suzhou) Technology Company (Asclepius (Suzhou) Technology) |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
Creative Biolabs offers an extensive selection of high-quality anti-BCMA recombinant antibodies tailored to meet your research needs. Our committed team guarantees timely delivery of both large and small orders, complemented by outstanding customer support. Contact us today to learn how our antibodies can elevate your research projects.